Trichomonas vaginalis in selected US sexually transmitted disease clinics: Testing, screening, and prevalence

Sexually Transmitted Diseases

Volumn 40, Issue 11, 2013, Pages 865-869

  Meites, Elissa ^a   Llata, Eloisa ^a   Braxton, Jim ^a   Schwebke, Jane R ^b   Bernstein, Kyle T ^c   Pathela, Preeti ^d   Asbel, Lenore E ^e   Kerani, Roxanne P ^f,g   Mettenbrink, Christie J ^h   Weinstock, Hillard S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^f Public Health   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIAGNOSTIC TEST; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MASS SCREENING; PREVALENCE; PUBLIC HEALTH SERVICE; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UNITED STATES;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; NITROIMIDAZOLES; PELVIC INFLAMMATORY DISEASE; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; UNITED STATES;

EID: 84885975272     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000038     Document Type: Article

References (31)

1. World Health Organization. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: Methods and results used by WHO to generate 2005 estimates. Geneva, Switzerland: World Health Organization, 2011.
2. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007; 45:1319-1326.
3. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta: U.S. Department of Health and Human Services, 2011.
4. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the APTIMATrichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012; 50:2601-2608.
5. Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2006; 33:747-752.
6. Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002; 34:519-522.
7. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
8. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344:246-248.
9. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008; 197:548-554.
10. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coitalact HIV-1 infectivity among African HIV-1Yserodiscordant couples. J Infect Dis 2012; 205:358-365.
11. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: A case for rescreening. Ann Intern Med 2006; 145:564-572.
12. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010; 59:1-110.
13. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012; 18:939-943.
14. Bosserman EA, Helms DJ, Mosure DJ, et al. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis Yinfected women with clinical treatment failure. Sex Transm Dis 2011; 38:983-987.
15. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44:13-22.
16. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007; 45:194-198.
17. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009; 200:188.e1-188.e7.
18. Andrea SB, Chapin KC. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification assay and BD Affirm VPIII for detection of T. vaginalis in symptomatic women: Performance parameters and epidemiological implications. J Clin Microbiol 2011; 49:866-869.
19. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective US clinical trial. J Clin Microbiol 2011; 49:4106-4111.
20. Bachmann LH, Hobbs MM, Seña AC, et al. Trichomonas vaginalis genital infections: Progress and challenges. Clin Infect Dis 2011; 53(suppl 3):S160YS172.
21. Rietmeijer CA, Donnelly J, Bernstein KT, et al. Here comes the SSuN: Early experiences with the STD Surveillance Network. Public Health Rep 2009; 124:72-77.
22. Helms DJ, Mosure DJ, Metcalf CA, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis 2008; 35:484-488.
23. Johnson HL, Ghanem KG, Zenilman JM, et al. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex Transm Dis 2011; 38:167-171.
24. Centers for Disease Control and Prevention. HIV surveillance VUnited States, 1981-2008. MMWR 2011; 60:689-693.
25. Hoots BE, Peterman TA, Torrone EA, et al. A trich-y question: Should Trichomonas vaginalis infection be reportable? Sex Transm Dis 2013; 40:113-116.
26. Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for Chlamydia trachomatis: A review of published studies. Sex Transm Infect 2002; 78:406-412.
27. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006; 55:1-17.
28. Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003:CD000218.
29. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
30. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009; 36:11-16.
31. Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012; 39:638-642.